Acknowledgement
This work was supported by the research fund of Chungnam National University.
References
- Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation 2022;145:e4-17.
- Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021;42:1289-367.
- Sinnaeve PR, Adriaenssens T. Dual antiplatelet therapy de-escalation strategies. Am J Cardiol 2021;144 Suppl 1:S23-31.
- Palmerini T, Bruno AG, Redfors B, et al. Risk-benefit of 1-year DAPT after DES implantation in patients stratified by bleeding and ischemic risk. J Am Coll Cardiol 2021;78:1968-86.
- Natsuaki M, Morimoto T, Yamaji K, et al. Prediction of thrombotic and bleeding events after percutaneous coronary intervention: CREDO-Kyoto thrombotic and bleeding risk scores. J Am Heart Assoc 2018;7:e008708.
- Simonsson M, Alfredsson J, Szummer K, Jernberg T, Ueda P. Association of ischemic and bleeding events with mortality among patients in Sweden with recent acute myocardial infarction receiving antithrombotic therapy. JAMA Netw Open 2022;5:e2220030.
- Park JS, Jeong YH. Unguided de-escalation strategy from potent P2Y12 inhibitors in patients presented with ACS: when, whom and how? Korean Circ J 2022;52:320-3.
- Capodanno D, Bhatt DL, Gibson CM, et al. Bleeding avoidance strategies in percutaneous coronary intervention. Nat Rev Cardiol 2022;19:117-32.
- Steensig K, Olesen KK, Madsen M, et al. A novel model for prediction of thromboembolic and cardiovascular events in patients without atrial fibrillation. Am J Cardiol 2020;131:40-8.
- Song YB, Oh SK, Oh JH, et al. Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): a prospective multicenter randomized trial. Am Heart J 2018;197:77-84.
- Choi KH, Park YH, Song YB, et al. Long-term effects of P2Y12 inhibitor monotherapy after percutaneous coronary intervention: 3-year follow-up of the SMART-CHOICE randomized clinical trial. JAMA Cardiol 2022;7:1100-8.
- Capodanno D, Morice MC, Angiolillo DJ, et al. Trial design principles for patients at high bleeding risk undergoing PCI: JACC scientific expert panel. J Am Coll Cardiol 2020;76:1468-83.
- Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407-77.
- Wurtz M, Olesen KK, Mortensen MB, et al. Dual antithrombotic treatment in chronic coronary syndrome: European Society of Cardiology criteria vs. CHADS-P2A2RC score. Eur Heart J 2022;43:996-1004.
- Leiter LA, Bhatt DL, McGuire DK, et al. Diabetes-related factors and the effects of ticagrelor plus aspirin in the THEMIS and THEMIS-PCI trials. J Am Coll Cardiol 2021;77:2366-77.
- Zhu H, Xu X, Fang X, et al. Efficacy and safety of long-term antithrombotic strategies in patients with chronic coronary syndrome: a network meta-analysis of randomized controlled trials. J Am Heart Assoc 2021;10:e019184.
- Armstrong PC, Dhanji AR, Truss NJ, et al. Utility of 96-well plate aggregometry and measurement of thrombi adhesion to determine aspirin and clopidogrel effectiveness. Thromb Haemost 2009;102:772-8.
- Armstrong PC, Dhanji AR, Tucker AT, Mitchell JA, Warner TD. Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. J Thromb Haemost 2010;8:613-5.
- Armstrong PC, Leadbeater PD, Chan MV, et al. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. J Thromb Haemost 2011;9:552-61.
- Kinlay S, Quach L, Cormack J, et al. Premature discontinuation of dual antiplatelet therapy after coronary stenting in veterans: characteristics and long-term outcomes. J Am Heart Assoc 2021;10:e018481.
- Dehghani P, Cao D, Baber U, et al. Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. Eur Heart J Cardiovasc Pharmacother 2022;8:707-16.
- Giustino G, Chieffo A, Palmerini T, et al. Efficacy and safety of dual antiplatelet therapy after complex PCI. J Am Coll Cardiol 2016;68:1851-64.
- Gragnano F, Mehran R, Branca M, et al. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after complex percutaneous coronary interventions. J Am Coll Cardiol 2023;81:537-52.
- Lee YJ, Suh Y, Kim JS, et al. Ticagrelor monotherapy after 3-month dual antiplatelet therapy in acute coronary syndrome by high bleeding risk: the subanalysis from the TICO trial. Korean Circ J 2022;52:324-37.
- Park MW. Balancing between ischemic and bleeding risk in PCI patients with 'bi-risk'. Korean Circ J 2022;52:338-40.